Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ivabradine

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

FDA rejects Amgen’s osteoporosis hope romosozumab

Its partner UCB plans to submit the medicine for European approval later this year

- PMLiVE

Amgen aspires to new Kyprolis label in the US and Europe

Appeals to regulators to add survival data to multiple myeloma drug's labelling

- PMLiVE

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

- PMLiVE

Amgen sues Sanofi and Regeneron over eczema drug

Alleges patent infringement and seeks financial reparations

- PMLiVE

Amgen wins European approval for Humira biosimilar Amgevita

European Commission approves the first version of AbbVie's blockbuster

Novartis day

What future for serelaxin after phase III miss?

Novartis' acute heart failure therapy misses two main endpoints

- PMLiVE

Repatha outcomes data “less than stellar”

Analysts underwhelmed by latest results on Amgen's drug despite it seeing some improvements

- PMLiVE

NICE set to back Parsabiv for kidney disease complication

Draft guidance recommends Amgen treatment for secondary hyperparathyroidism

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Hopes ENDEAVOR trial results will give it an edge over Takeda's brand

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links